GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Merck & Co Inc (MEX:MRK) » Definitions » Change In Payables And Accrued Expense

Merck (MEX:MRK) Change In Payables And Accrued Expense : MXN0 Mil (TTM As of Mar. 2024)


View and export this data going back to 1946. Start your Free Trial

What is Merck Change In Payables And Accrued Expense?

Merck's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2024 was MXN0 Mil. It means Merck's Accounts Payable & Accrued Expense stayed the same from Dec. 2023 to Mar. 2024 .

Merck's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was MXN27,447 Mil. It means Merck's Accounts Payable & Accrued Expense increased by MXN27,447 Mil from Dec. 2022 to Dec. 2023 .


Merck Change In Payables And Accrued Expense Historical Data

The historical data trend for Merck's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merck Change In Payables And Accrued Expense Chart

Merck Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Change In Payables And Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -19,482.38 6,882.63 2,912.99 799.34 27,447.36

Merck Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Change In Payables And Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Merck Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Merck Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Merck's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Merck (MEX:MRK) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Merck & Co Inc (MEX:MRK) » Definitions » Change In Payables And Accrued Expense
Address
126 East Lincoln Avenue, Rahway, NJ, USA, 07065
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.

Merck (MEX:MRK) Headlines

From GuruFocus

Q3 2023 Merck & Co Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Merck & Co Inc at UBS BioPharma Conference Transcript

By GuruFocus Research 01-23-2024

Merck & Co Inc Investor Event at ASCO 2023 Transcript

By GuruFocus Research 01-23-2024

Merck & Co Inc Annual Shareholders Meeting Transcript

By GuruFocus Research 01-23-2024

Merck & Co Inc Annual Shareholders Meeting Transcript

By GuruFocus Research 01-23-2024

Q4 2022 Merck & Co Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Merck & Co Inc at Citi BioPharma Conference Transcript

By GuruFocus Research 01-23-2024